| No dose escalation (3 mg/kg) at week 14 | Dose escalation (5 mg/kg) at week 14 | ||||
---|---|---|---|---|---|---|
 | PF-06438179/GP1111 (n = 240), n (%) | Infliximab-EU (n = 244), n (%) | Treatment difference, % | PF-06438179/GP1111 (n = 60), n (%) | Infliximab-EU (n = 68), n (%) | Treatment difference, % |
Week 22 | ||||||
ACR20 response | ||||||
 Yes | 180 (75.0) | 185 (75.8) | − 0.82 | 23 (38.3) | 27 (39.7) | − 1.37 |
 No | 58 (24.2) | 58 (23.8) |  | 36 (60.0) | 36 (52.9) |  |
 Missing | 2 (0.8) | 1 (0.4) |  | 1 (1.7) | 5 (7.4) |  |
Week 30 | ||||||
ACR20 response | ||||||
 Yes | 169 (70.4) | 181 (74.2) | − 3.76 | 27 (45.0) | 27 (39.7) | 5.29 |
 No | 65 (27.1) | 55 (22.5) |  | 29 (48.3) | 30 (44.1) |  |
 Missing | 6 (2.5) | 8 (3.3) |  | 4 (6.7) | 11 (16.2) |  |